Sugi Predict

Sugi Predict / Targets / PRKD3

PRKD3

Serine/threonine-protein kinase D3 · O94806 · PRKD3 on Sugi Atlas →

173,640 patent compounds predicted against PRKD3, 132,708 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Staurosporine Staurosporine (SCHEMBL8156) 1.00 10/20
Staurosporine Staurosporine (SCHEMBL8157) 1.00 10/20
Fasudil Fasudil (SCHEMBL4674) 1.00 5/20
SCHEMBL78989 SCHEMBL78989 0.62 5/20
Phorbol Phorbol (SCHEMBL72895) 0.62 5/20
SCHEMBL9306 SCHEMBL9306 0.89 4/20
Sb-203580 Sb-203580 (SCHEMBL95208) 0.75 4/20
SCHEMBL9305 SCHEMBL9305 0.74 4/20
SCHEMBL69095 SCHEMBL69095 0.67 4/20
SCHEMBL67376 SCHEMBL67376 0.64 4/20
SCHEMBL82376 SCHEMBL82376 0.63 4/20
Phorbol Phorbol (SCHEMBL64353) 0.62 4/20
SCHEMBL66923 SCHEMBL66923 0.60 4/20
SCHEMBL67192 SCHEMBL67192 0.60 4/20
Phorbol Phorbol (SCHEMBL14937) 0.60 4/20
SCHEMBL68165 SCHEMBL68165 0.59 4/20
Daph Daph (SCHEMBL11017) 1.00 3/20
Balanol Balanol (SCHEMBL62128) 1.00 3/20
Balanol Balanol (SCHEMBL62129) 1.00 3/20
Cinnamtannin B1 Cinnamtannin B1 (SCHEMBL94430) 1.00 3/20

Clinical trials — most relevant to PRKD3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) PHASE4UNKNOWN
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Tabectedin to Treat Children and Adolescents With Cancer PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer EARLY_PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Longitudinal Natural History Protocol for PRKN- and PINK1-Linked PD nanNOT_YET_RECRUITING
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKD3 binder may also engage these)

ProteinNameSimilarity
PRKD1 Serine/threonine-protein kinase D1 1.000 landscape →
Q8K1Y2 — 1.000 Q8K1Y2 →
Q9WTQ1 — 0.998 Q9WTQ1 →
Q5XIS9 — 0.992 Q5XIS9 →
A7MBL8 — 0.990 A7MBL8 →
Q62101 — 0.989 Q62101 →
Q8BWW9 — 0.986 Q8BWW9 →
Q9ESL4 — 0.986 Q9ESL4 →
PRKD2 Serine/threonine-protein kinase D2 0.986 landscape →
Q8BZ03 — 0.984 Q8BZ03 →
Q04982 — 0.984 Q04982 →
MAP3K20 Mitogen-activated protein kinase kinase kinase 20 0.983 landscape →
PKN2 Serine/threonine-protein kinase N2 0.982 landscape →
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3 0.981 landscape →
Q99JP0 — 0.980 Q99JP0 →
O08874 — 0.979 O08874 →
Q3LAC4 — 0.979 Q3LAC4 →
O60890 — 0.978 O60890 →
Q5PYH6 — 0.978 Q5PYH6 →
P00534 — 0.977 P00534 →
P0CAX5 — 0.977 P0CAX5 →
Q9WVQ1 — 0.976 Q9WVQ1 →
P28028 — 0.976 P28028 →
B2RQE8 — 0.976 B2RQE8 →
P34908 — 0.976 P34908 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.976 landscape →
Q90ZY6 — 0.976 Q90ZY6 →
Q5R6M6 — 0.975 Q5R6M6 →
Q5U4T3 — 0.975 Q5U4T3 →
Q6ZQ82 — 0.975 Q6ZQ82 →